Insights Into Hepatocellular Carcinoma (HCC)

Perspectives on current treatment practice attitudes toward therapy of unresectable advanced hepatocellular carcinoma (HCC), recently introduced and upcoming agents

Pacific Northwest March 15, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

California March 16, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

Hawaii, Southern California, Phoenix June 15, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

Denver and Kansas City June 22, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

Houston, San Antonio, South Texas October 5, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

Dallas October 6, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

Southeast November 30, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

Northeast December 1, 2021

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ

More information

  • Virtual Series
  • Oregon, Washington

More Information

  • Virtual Series
  • California

More Information

  • Virtual Series
  • Hawaii, Southern California, Phoenix

More Information

  • Virtual Series
  • Denver and Kansas City

More Information

  • Virtual Series
  • Houston, San Antonio, South Texas

More Information

  • Virtual Series
  • Dallas

More Information

  • Virtual Series
  • Florida, Georgia, North Carolina, South Carolina

More Information

  • Virtual Series
  • New York, Boston

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of hepatocellular carcinoma
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.